Pressure Builds In Ventricular Assist Market
With only two companies, Thoratec and HeartWare International, selling LVADs in the US, clinical data along with sales and product pipeline strategies have become paramount for capturing market share – and expanding the market to treat a wide range of class III heart failure patients.
You may also be interested in...
Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.
With the rivalry between Thoratec and HeartWare intensifying in the LVAD space, all eyes are now on recent strategic acquisitions by both companies, as well as ongoing clinical studies and next-generation devices in the pipeline.
Several stakeholders are still pushing CMS to recognize “bridge-to-decision” heart failure patients who may eventually be suitable for a heart transplant but are not so at the time they receive a ventricular assist device.